Abstract: The invention provides methods of hair loss or inducing new hair growth, as well as methods of preventing hair loss, comprising applying an effective amount of a dihydromyricetin compound to the scalp. The invention also provides methods of delaying or reversing signs of aging skin comprising applying an effective amount of a dihydromyricetin compound to the skin. Also provided are cosmetic products (e.g., skin and hair products) comprising a dihydromyricetin compound and methods of making the same.

Abstract: A composition for hair regrowth and hair growth stimulation, a method of use therefore, and a method of making. In an embodiment, the invention is directed toward a hair regrowth and growth stimulant containing the active ingredient minoxidil in combination with a stem cell activating hair growth/regrowth promoter in a non-irritating vehicle/carrier formulation. The non-irritating and scalp-friendly embodiments of the invention are particularly useful in methods for treating all hair types and ethnicities, and are especially useful in the treatment of African-American patients suffering from various forms of non-androgenetic alopecia.

Abstract: A dermatological and/or topical composition, which contains retinaldehyde, and DNA.

Abstract: The invention relates to a composition which contains an aqueous solution of certain elements of a family of sterol derivatives, which enable improved tanning of the skin due to considerable penetration of the molecules thereof. Preferably, the composition also contains an ionic solution of cationic association complexes constituting an acid amphiphilic carrier.

Abstract: The present invention provides a skin care composition for maintaining or improving the healthy appearance of the skin of an individual and/or rejuvenate the skin of an individual. A skin care composition comprises active ingredients, including, without limitation, growth factors, anti-oxidants, curcuminoids, oils and/or red rice extracts. Among the growth factors comprising biologically active ingredients of the skin care composition are insulin like growth factor (IGF), an epidermal growth factor protein (EGFP), an insulin-like growth factor (IGF), a transforming growth factor beta (TGF?), and erythropoiesis stimulating agent (ESA). The invention further provides a skin care composition for topical use to maintain or improve the health of the skin of an individual and/or rejuvenate the skin of an individual.

Abstract: A subject of the present invention is an anhydrous composition comprising: a) at least particles encapsulating at least one beneficial agent, the particles being able to release the beneficial agent in the presence of water; b) at least one sebum-absorbing powder with a sebum uptake of greater than or equal to 35 ml/100 g, and/or at least one styling powder other than the particles encapsulating at least one beneficial agent; c) optionally a propellant. A subject of the present invention is also to a process for the dry-washing and cosmetic treatment of keratin materials, comprising a step of applying the composition to the hair.

Abstract: The invention relates to an antiperspirant cosmetic agent which includes at least one specific chitosan and which is free of aluminum-containing compounds, in particular free of halides and/or hydroxy halides of aluminum and/or zirconium. The present invention further relates to the use of a specific chitosan and to a non-therapeutic method for reducing body perspiration. Adding or using the at least one specific chitosan ensures that the sweat gland(s) is/are effectively influenced, thus resulting in a significant reduction in underarm perspiration even in the absence of antiperspirant aluminum-containing compounds.

Abstract: The present invention relates to a makeup and/or care composition in the form of an emulsion comprising: a. at least one film-forming polymer chosen from vinyl polymers comprising at least one carbosiloxane dendrimer-based unit, b. at least 2% by weight of at least one non-volatile oil, c. at least one silicone gum chosen from polyorganosiloxanes with a weight-average molecular mass of at least 400000 g/mol, d. water. The present invention also relates to a process for making up and/or caring for the lips, comprising the application to the lips of a composition according to the invention. Finally, the present invention relates to a device comprising the composition according to the invention.

Abstract: An agent for temporarily changing the colour of keratin fibres, in particular human hair, include in an aqueous cosmetic carrier (a) at least one aliphatic and/or aromatic alcohol having 2-8 C atoms (b), at least one colour pigment, and (c) at least one zwitterionic polymer, the total weight of the solid matter (d) included in the agent, with respect to the total weight of the agent, being less than 2.5 wt. %.

Abstract: The invention relates to a copolymer resulting from the polymerization of: (a) 50% to 90% by weight, of the total weight of monomers, of isobornyl (meth)acrylate, (b) 1% to 50% by weight of maleic anhydride, (c) 0% to 49% by weight of additional (meth)acrylate monomer chosen from: (i) saturated or unsaturated and linear or branched C1-C20 alkyl (meth)acrylates, the alkyl being optionally interrupted by one or more nonadjacent heteroatoms chosen from O or S or by an NR group, R being a C1-C4 alkyl group, optionally substituted by a phenyl or furfuryl group; (ii) saturated C4-C8 cycloalkyl (meth)acrylates, the cycloalkyl being optionally interrupted by O or NH. The invention also relates to a composition comprising said copolymer in a physiologically acceptable medium. The invention also relates to a cosmetic method for caring for or making up the skin or the lips, comprising the topical application, to the skin or the lips, of a cosmetic composition comprising said copolymer.

Abstract: The present invention relates to cosmetic agents for temporarily deforming keratinous fibers comprising—relative to the total weight thereof—a) 0.1 to 2.0 w % of at least one hydrophobically modified (meth) acrylic acid copolymer and b) 0.2 to 12 wt % of at least one polymeric quaternary ammonium compound from the group of vinylpyrrolidone copolymers, to the use thereof, and to methods using said agents.

Abstract: A powder dispersant includes an ester compound of a polyglycerol having an average degree of polymerization of the polyglycerol, calculated from its hydroxyl value, in the range 2 to 20, a monovalent carboxylic acid or at least one derivative thereof, and a divalent carboxylic acid or at least one derivative thereof.

Abstract: The present invention relates to a cosmetic composition for fixing hair or for temporarily shaping keratinous fibers, in particular, human hair, with which composition an excellent resistance to humidity is achieved, wherein the composition includes a combination of polyvinylpyrrolidone (PVP) and polyurethene-polyacrylate hybrid polymer.

Abstract: The invention relates to a method for producing a cosmetic composition, comprising at least one polyurethane urea which does not contain any ionically hydrophilizing groups and is dissolved in a solvent or solvent mixture, wherein the solvent consists of one or more monohydroxy-functional alcohol(s), or a solvent mixture that consists of organic solvents and contains ?50 wt. %, relative to the total weight of the solvent mixture, of at least one monohydroxy-functional alcohol. The invention also relates to a cosmetic composition obtainable according to the method of the invention as well as to a method for forming a cosmetic coating on skin, nails and/or keratin fibers using the cosmetic compositions of the invention. The invention further relates to a sunscreen composition containing a polyurethane urea as well as to said sunscreen composition for protecting skin and/or hair from negative effects of sun rays.

Abstract: The present invention relates to a process for producing a nail varnish composition, characterized in that at least one polyurethane urea which has no ionically hydrophilizing groups and has been dissolved in a solvent or solvent mixture is used, the solvent comprising one or more monohydroxy-functional alcohols or being a solvent mixture comprising organic solvents and containing ?50% by weight, based on the total mass of the solvent mixture, of at least one monohydroxy-functional alcohol. The present invention further relates to a nail varnish composition obtainable by the process according to the invention and to a process for producing a cosmetic coating on nails using the nail varnish compositions according to the invention.

Abstract: The application relates to oral care compositions comprising substantive polyesteramides formed from polyols, polycarboxylic acids (or esters, anhydrides or halides thereof) and arginine. The formed polyesteramides are active in biofilm inhibition, biofilm dissolution and retarding or preventing acid production from oral bacteria.

Abstract: Oral compositions containing a polyorganosilsesquioxane particle, preferably polymethylsilsesquioxane particles, an oxidizing agent and an orally-acceptable carrier. Method of using such compositions for the cleaning and polishing of dental enamel, such methods including the step of applying such oral care compositions to the teeth of a user.

Abstract: Agents for temporarily changing the color of keratinous fibers, in particular human hair, include in an aqueous cosmetic carrier—relative to the total weight of the agent—(a) at least 20 wt % one or more aliphatic and/or aromatic alcohols having 2 to 8 C atoms, (b) at least one color pigment and (c) at least one non-ionic polyalkoxylated silicone, wherein the total amount of the fatty substances (d) included in the agent is at a value below 2.5 wt %.

Abstract: Disclosed is a Japanese camellia extract, obtained by extracting Camellia japonica flowers by way of a fatty substance or fatty substance mixture, and to a cosmetic composition including one such extract that has, in particular, a skin-moisturizing effect.

Abstract: Methods are disclosed for the collection and processing of amniotic material in animals. These methods involve collection of amniotic material directly during parturition or cesariean section in animals for the processing of regenerative wound treatments and tissue repairs without culturing or utilization of any excess manipulation of tissue. These materials are used to effect a cosmetic result.

Abstract: The invention is directed to sublingual spray formulations containing sildenafil. The invention is further directed to methods of treating male sexual dysfunction or pulmonary arterial hypertension by administering sublingual spray formulations containing sildenafil to patients in need of such treatments.

Abstract: The present invention relates generally to topical antiviral compositions and methods of using the same.

Abstract: A method of subcutaneous delivery of a drug or a therapeutic agent to a subject comprising administering to said subject a mass of fluid of a tumescent composition comprising: (a) the drug or the therapeutic agent; (b) a vasoconstrictor; and (c) a pharmaceutically acceptable carrier, wherein a relatively large total amount of the drug is isolated from systemic circulation in the subject because only drug in an outer boundary of the mass of fluid is the available for absorption, whereas a portion of the drug located within a central portion of the mass of fluid is virtually isolated from the systemic circulation by virtue of profound capillary vasoconstriction, wherein epinephrine-induced vasoconstriction dramatically slows systemic absorption of the drug or therapeutic agent, and wherein the mass of fluid is a reservoir that delivers the drug or the therapeutic agent to the subject with pharmacokinetics that are analogous to a slow-release oral tablet or a slow constant intravenous (IV) Infusion.

Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.

Abstract: Dendrimer-based compositions and methods are provided, that are useful for administering pharmaceutical compositions to target cells and tissues for treatment of ocular diseases including macular degeneration, diabetic retinopathy, and retinitis pigmentosa.

Abstract: The present disclosure relates to fibers implantable in the body of a human or animal and processes for manufacturing such a fiber. The fiber undergoes a reduction in surface area to volume ratio of a factor of 1.05-10 upon injection in the human or animal body. In an embodiment, a process for manufacturing a fiber comprises extruding a biodegradable polymer into a fiber capable of fitting in a syringe needle of at least 25 Gauge, and cooling the fiber below its dry glass transition temperature while the fiber is under tension.

Abstract: The invention provides a method of making a composition for inhalation which includes the step of mixing particles of additive material having a diameter of not more than 2 ?m with active particles, wherein the additive material is suitable for promoting the dispersal of active particles upon aerolisation of a dry powder in a dry powder inhaler.

Abstract: The present invention is concerned with a refinement of the processing of particles that are to form a dry powder formulation which is to be administered to the lung using a dry powder inhaler (DPI) device. In particular, the present invention provides the processing of particles of active material and particles of carrier material in the presence of additive material to provide a powder composition which exhibits excellent powder properties and which is economical to produce.

Abstract: The invention provides liquid compositions in the form of physically stable emulsions comprising a semifluorinated alkane. The semifluorinated alkane is comprised in the dispersed phase, which may also include an active pharmaceutical ingredient. One of the preferred active ingredients is propofol. The compositions are optionally heat sterilisable and can be used for pharmaceutical or cosmetic product applications, and administered topically, intravenously, or via other routes.

Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

Abstract: A multi-component nanochain for use in diagnostic and therapeutic applications includes at least three nanoparticles linked together to form the nanochain. At least one nanoparticle of the nanochain has an asymmetric surface chemistry defined by asymmetrically disposed first linkers and second linkers. The nanoparticles are linked to form the nanochain by linking first linkers and/or second linkers disposed on separate nanoparticles.

Abstract: Fine dry particulate adenosine compositions suitable for use in topical formulations, as well as methods of making the same, are provided. In the dry particulate adenosine composition, the adenosine active agent is associated with the particles, e.g., via entrapment in the pores of the particles and/or ionic binding and/or non-covalent binding to the surface of the particles and/or loosely associated with the particles. Also provided are topical formulations which include the dry particulate adenosine compositions of the invention, and methods of using the same.

Abstract: The invention relates to matrix and layer compositions comprising a first polymer. The matrix and layer compositions are useful in the delivery of bioactives. In particular, the matrices and layers may have advantageous properties including mechanical properties and protection of bioactives and may also provide for pH-dependent release of a bioactive.

Abstract: The present invention relates to compositions comprising at least one lactose component, at least one cellulose component and at least one starch component, its preparation and its use, particularly as a direct tabletting excipient.

Abstract: The present invention relates to a preparation method of drug-containing sustained release microparticles, the preparation method comprising the steps of: (a) dissolving a biodegradable polymer and a drug in a halogenated alkane solvent to form a drug-containing biodegradable polymer solution; (b) homogeneously mixing the drug-containing biodegradable polymer solution in a continuous phase containing a surfactant to form a dispersed phase; (c) maintaining an emulsion comprising the continuous phase and the dispersed phase at a temperature lower than the boiling point of the halogenated alkane solvent to form microparticles in the continuous phase; (d) primarily drying the microparticles; (e) mixing the primarily dried microparticles with an aqueous alcohol solution, and then maintaining the aqueous alcohol solution at a temperature no less than the boiling point of the halogenated alkane solvent to extract and evaporate the remaining halogenated alkane solvent from the microparticles; and (f) secondarily dryi

Abstract: The invention relates to an aqueous granulation process for preparing granules comprising an amorphous poorly water soluble active pharmaceutical ingredient, a particular polymer and a particular surfactant. The invention also refers to a process for preparing tablets comprising said granules. Furthermore, the invention refers to granules and tablets obtainable by the process of the invention.

Abstract: The present invention provides a method of treating pain and pain related conditions by administering to a patient in need thereof, a therapeutically effective amount of a slow release Tapentadol Hydrochloride and therapeutically effective amount of a second analgesic, wherein the second analgesic is gamma-aminobutyric acid (GABA) analogue. The present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a slow release Tapentadol Hydrochloride and a therapeutically effective amount of a second analgesic, wherein the second analgesic is gamma-aminobutyric acid (GABA) analogue.

Abstract: The present invention relates to directly compressible co-mixtures for the production of tablets having delayed release of active compound which comprise polyvinyl alcohols (PVAs) and microcrystalline celluloses (MCCs).

Abstract: The present invention relates to a hygroscopic matrix based composition, a process for the preparation thereof and its use in the treatment of diseases.

Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.

Abstract: Salt formulations, which are resistant to moisture and cooking conditions, are described herein. The formulations provide particles of micronutrients and vitamins encapsulated within heat resistant pH-sensitive water-insoluble polymers, which are packaged within a salt shell. The pH-sensitive, water-insoluble, thermally stable materials stabilize the micronutrients, particularly at high temperatures, such as during food preparation and cooking, and release the micronutrients at the desired locations such as the stomach, small intestine, etc. Preferred pH-sensitive polymers release at a low pH, less than the pH present in the stomach. The particles can be used to deliver daily-recommended doses of micronutrients simultaneously with salt, eliminating the need for vitamin pills. This is particularly important in populations suffering from severe malnutrition.

Abstract: In one embodiment, the present invention provides a composition comprising a plurality of microcapsules, each comprising a shell and a core carrying an active agent selected from the group consisting of: (a) a non-hydrophilic active agent and (b) a hydrophilic active agent dissolved or suspended in an oil; wherein the shell comprises a polymeric coating, and wherein at least a portion of the microcapsules in a sample of the composition are spherical when the sample of the microcapsules is viewed in a scanning electron microscope with a magnification in the range of between ×2000 and ×50000.

Abstract: This disclosure relates to nanoparticles, compositions, methods of making, and methods of use thereof.

Abstract: Nanoparticles containing a mitochondrial that are capable of crossing the blood-brain barrier and that have a targeting moiety, an antioxidant and an anti-inflammatory agent may be useful for treatment of traumatic brain injury.

Abstract: A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in a polymeric film forming system. Advantageously, the film oral dosage form further includes a sweetener, a refreshing agent, an antioxidant, a pH stabilizer, a penetration enhancer, a mucoadhesive agent and a plasticizer. The loxapine film oral dosage form provides rapid onset of relief from acute agitation associated with schizophrenia or bipolar 1 disorder without presenting pulmonary health risks, thereby reducing risks to patients and others.

Abstract: Methods and compositions are disclosed for delivering lutein or other antioxidant to target tissues such as the eye, in bioactive form, while protecting the antioxidant from degradation. The antioxidant is encapsulated in nanoparticles comprising a protein such as zein or a polymer such as poly(lactic-co-glycolic acid) (PLGA). Preferably a surfactant is associated with the nanoparticles as well, further helping to protect the antioxidant. After the nanoparticles are administered to the target tissue, bioactive antioxidant is released to the tissue over time. Optionally, the nanoparticles are admixed with a thermosensitive, bioadhesive gel to promote slow release of antioxidant. The methods and compositions are useful for treating or preventing conditions such as age-related macular degeneration or cataracts.

Abstract: Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.

Abstract: The invention provides methods and compositions for treatment of a subject with a solid tumor comprising administration of Coenzyme Q10 (CoQ10), particularly when the subject has failed at least one prior chemotherapeutic regimen.

Abstract: The present invention generally relates to improvements in the bioavailability and/or solubility of coenzyme Q10. For example, the present invention relates to methods for preparing particulate compositions including coenzyme Q10 that generally comprise dispersing and/or dissolving the coenzyme Q10 throughout a suitable solvent, and combining the coenzyme Q10 and an encapsulating (e.g., microencapsulating) agent. The present invention also generally relates to particulate compositions comprising coenzyme Q10 that exhibit improved bioavailability and/or solubility as compared to previous coenzyme Q10 products.

Abstract: The invention provides a method for anticoagulation, including administering to a subject in need a therapeutically effective amount of pharmaceutical composition including formula (I) or its isomers as its parent form, and its salt, ester or solvate. The invention also provides a method for anticoagulation, including administering to a subject in need a therapeutically effective amount of pharmaceutical composition including formula (I) or its isomers as its parent form, and its salt, ester or solvate for at least 1 hour, wherein a dose of the pharmaceutical composition is in an amount of about 5×10?5 mL/kg or more of body weight of the subject.